FOXO4-DRI
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
FOXO4-DRI is a synthetic senolytic peptide — a compound designed to selectively clear senescent cells, the aged, dysfunctional “zombie” cells that stop dividing but refuse to die and instead accumulate with age, driving inflammation and tissue decline. “DRI” stands for D-retro-inverso: the peptide is built from D-amino acids in reverse sequence, a design trick that makes it far more resistant to enzymatic breakdown than a normal peptide. It was developed in the lab of Peter de Keizer. It sits in the same longevity neighborhood as the telomerase/senescence work — see Epithalon for the Khavinson-school longevity angle on a different mechanism.
What does it do in my body?
In senescent cells, the transcription factor FOXO4 binds and sequesters p53, keeping those cells alive instead of letting them undergo apoptosis (programmed cell death). FOXO4-DRI is designed to disrupt the FOXO4–p53 interaction, freeing p53 to trigger apoptosis selectively in senescent cells while sparing healthy ones. The appeal is targeting: clear the senescent burden, leave normal tissue alone.
How can it help me?
- Where the science stands: One landmark mouse study (Cell, 2017); zero published human trials
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
Unknown in humans. No human trials means no documented human side-effect profile exists to report, positively or negatively. Treat the absence of data as exactly that — an absence, not a clean bill of health.
Regulatory status: Research compound — not approved for human use, not eligible for compounding. Tier D / encyclopedia-only: a promising mechanism with no human data behind it. The senolytic category is one of the most-watched in longevity science; FOXO4-DRI specifically is still a one-landmark-study compound.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
There isn’t one to give honestly. FOXO4-DRI has no human dosing data, no human safety data, and no established real-world protocol — anything claiming otherwise is not backed by the evidence captured here. This is a research compound, not a self-directed protocol candidate.
What should I avoid combining — and what's synergistic?
FOXO4-DRI doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
A synthetic senolytic peptide built on one striking mouse study and a clean mechanistic story — and, as of today, nothing else. This is the honest frontier: real biology, zero human data, encyclopedia-only.
| Class | Synthetic D-retro-inverso (DRI) peptide — built from D-amino acids in reverse sequence for enzymatic stability |
| Mechanism (one line) | Disrupts the FOXO4–p53 interaction inside senescent cells, freeing p53 to trigger apoptosis selectively in “zombie” cells |
| Evidence base | One landmark mouse study (Cell, 2017); zero published human trials |
| Safety record | No human safety record at all — not established, not disproven |
| Regulatory status | Research compound only; not approved for human use, not eligible for compounding |
What it is
FOXO4-DRI is a synthetic senolytic peptide — a compound designed to selectively clear senescent cells, the aged, dysfunctional “zombie” cells that stop dividing but refuse to die and instead accumulate with age, driving inflammation and tissue decline. “DRI” stands for D-retro-inverso: the peptide is built from D-amino acids in reverse sequence, a design trick that makes it far more resistant to enzymatic breakdown than a normal peptide. It was developed in the lab of Peter de Keizer. It sits in the same longevity neighborhood as the telomerase/senescence work — see Epithalon for the Khavinson-school longevity angle on a different mechanism.
How it works
In senescent cells, the transcription factor FOXO4 binds and sequesters p53, keeping those cells alive instead of letting them undergo apoptosis (programmed cell death). FOXO4-DRI is designed to disrupt the FOXO4–p53 interaction, freeing p53 to trigger apoptosis selectively in senescent cells while sparing healthy ones. The appeal is targeting: clear the senescent burden, leave normal tissue alone.
What the research shows
Animal — the entire evidence base. The famous result is a single mouse study (Cell, 2017) showing senescent-cell clearance plus a measurable healthspan effect — restored fitness, fur density, and kidney function in aged and progeroid mice. That paper is the entire reason anyone is talking about this molecule.
Human — none. Beyond the 2017 mouse paper, the directory profile that anchors this entry lists zero published clinical studies on PubMed and grades the evidence anecdotal: 0 studies cited, 0 human trials. So: a striking, well-known mouse result, a clean mechanistic story, and no human safety record at all.
Real-world protocol
There isn’t one to give honestly. FOXO4-DRI has no human dosing data, no human safety data, and no established real-world protocol — anything claiming otherwise is not backed by the evidence captured here. This is a research compound, not a self-directed protocol candidate.
Side effects & management
Unknown in humans. No human trials means no documented human side-effect profile exists to report, positively or negatively. Treat the absence of data as exactly that — an absence, not a clean bill of health.
Regulatory status
Research compound — not approved for human use, not eligible for compounding. Tier D / encyclopedia-only: a promising mechanism with no human data behind it. The senolytic category is one of the most-watched in longevity science; FOXO4-DRI specifically is still a one-landmark-study compound.
Sources
- (thepeptidelist.com directory capture, 2026-06-07)
- Tier D / encyclopedia-only grading
- Key citation: FOXO4-DRI Cell 2017 mouse senescence-clearance study
- Migrated from
frontier-investigational-peptides-cluster.md(Section 1)
Sources & references
- (thepeptidelist.com directory capture, 2026-06-07)
- Tier D / encyclopedia-only grading
- Key citation: FOXO4-DRI Cell 2017 mouse senescence-clearance study
- Migrated from
frontier-investigational-peptides-cluster.md(Section 1)